[Form 4] Lexaria Bioscience Corp. Warrant Insider Trading Activity

Rhea-AI Filing Summary

Lexaria Bioscience Corp. (LEXX) Form 4: President, CSO and Director John M. Docherty disclosed an open-market purchase of 5,376 common shares on 07/29/2025 at $0.928 per share (≈$5,000 total). This lifts his direct holding to 5,376 shares and leaves indirect ownership unchanged at 54,075 shares via a private entity.

Docherty also reports 310,834 vested stock options with strike prices ranging from $1.04 to $3.00 and expirations between 2026-2030; no option transactions occurred.

Key takeaways: 

• First reported insider buy since options grants in 2024-2025.
• Purchase price sits below most option strike levels, highlighting current market discount.
• Transaction is modest in size but may signal management confidence amid a depressed share price.

Insights

Equity Analyst

TL;DR: Small insider buy; signals confidence, limited financial impact.

Docherty’s $5k purchase marginally increases his skin in the game and provides a psychological positive for investors given LEXX’s low trading range. However, the tiny volume (<1% of daily turnover) and already large option exposure mean the economic effect is immaterial. Still, insider buying—especially by a C-suite director—historically correlates with improved near-term returns, so sentiment skew is mildly bullish.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

DOCHERTY JOHN MARTIN

(Last) (First) (Middle)

23 MIKELEN DRIVE

(Street)

PORT PERRY A6 L9L 1V1

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexaria Bioscience Corp. [ LEXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CSO

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
common shares								54,075	I	Private Holding Company
common shares	07/29/2025		P		5,376	A	$0.928	5,376	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$3							04/26/2021	04/26/2026	Common Shares	18,000		18,000	D
Stock Options	$3							06/08/2021	06/08/2026	Common Shares	18,334		36,334	D
Stock Options	$3							09/01/2021	09/01/2026	Common Shares	15,000		51,334	D
Stock Options	$2.91							08/29/2022	08/29/2027	Common Shares	30,000		81,334	D
Stock Options	$1.15							10/26/2023	10/26/2028	Common Shares	30,000		111,334	D
Stock Options	$2.36							04/26/2024	04/26/2029	Common Shares	49,500		160,834	D
Stock Options	$1.04							05/15/2025	05/15/2030	Common Shares	150,000		310,834	D

Explanation of Responses:

	/John Docherty/	07/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Lexaria (LEXX) shares did John Docherty buy?

5,376 common shares were purchased on 07/29/2025.

At what price were the shares purchased?

The shares were bought at $0.928 each.

What is Docherty’s total direct share ownership after the transaction?

He now directly owns 5,376 common shares.

How many stock options does the executive hold?

Docherty beneficially holds 310,834 options with strikes between $1.04 and $3.00.

Is the transaction considered insider buying or selling?

It is insider buying (Transaction Code ‘P’).

Does the filing indicate any option exercises?

No, the form lists existing options only; no exercises or disposals occurred.